Analyzing a Current Healthcare Problem or Issue

Student name

Capella University

NURS-FPX4000

Professor name

Submission date

Analyzing a Current Healthcare Problem or Issue

For nearly two decades, the United States has struggled with the opioid epidemic, which has caused billions of dollars of damage to the healthcare system due to the number of lives lost and the number of individuals who suffer long-term damage because of their opioid use. Although there are effective evidence-based treatment options available to adults with opioid use disorder (OUD), individuals with OUD face substantial barriers to accessing treatment (Dowell et al., 2024). This assessment will use an analysis of the opioid epidemic as a means of encouraging organized problem-solving to improve healthcare and public policy decisions related to OUD and treatment for OUD.

Explaining the Healthcare Problem

The opioid epidemic continues to be a significant public health challenge in the U.S., contributing to a substantial amount of morbidity and mortality, as well as enormous financial burden for our society. In 2022, there were 107,941 drug overdose deaths recorded, which is approximately 32.6 deaths per 100,000 people (age-adjusted), compared to the 2002 rate of approximately 4,000 deaths, and an average of 296 drug overdoses daily (Spencer et al., 2023). Most of the deaths are now due to synthetic opioids, specifically fentanyl; in 2022 there were 22.7 deaths per 100,000 individuals due to synthetic opioids, which is an increase from 0.8 deaths per 100,000 in 2013 (Spencer et al., 2023). Additionally, according to Florence et al. (2021), the total cost of health care, work-related, and criminal justice losses related to opioid use exceeds $1 trillion.

This represents a small portion of the individuals with opioid use disorder (OUD) have had access to medications necessary to treat their disorder (methadone/Buprenorphine/naltrexone) within the prior year (Dowell, 2024). In 2022, a total of 25.1% of adults in the U.S. with OUD received medications for OUD (MOUD), including either Methadone or Buprenorphine, which are effective, safe medication for reducing to overdose and death, (Dowell, 2024) while 42.7% felt they did not need treatment, and 30% received treatment without the use of medication. Geographic inequities contribute to the treatment gap; nearly 19% of counties in the U.S. do not have at least one prescriber of Buprenorphine to treat OUD (Bettelheim, 2024). Other factors include socioeconomic and demographic disparities (Dowell, 2024).

It is critical to fill these emerging voids in OUD treatment. Provider education, accessibility through primary and mental health care, removing barriers to access for MAT, and providing harm-reduction interventions, such as naloxone distribution and supervised consumption sites, may greatly lessen overdose deaths and promote long-term recovery in the treatment of OUD. The opioid crisis has put health systems under strain, has robbed individuals and communities of health, and has undermined regional economies. This underlines the necessity for scaling up equitably implementable interventions with strong evidence.

Analyzing Issue Significance Thoroughly

 The opioid crisis has impacted all components of the health care system from emergency departments to inpatient units, through outpatient follow-up care, and beyond; communities and homes are also fighting the crisis as patients recover. The opioid crisis is a significant and relevant crisis that impacts nursing practice and therefore all nurses must assess patient pain level, provide guidance to patients about harm reduction strategies, as well as assist patients with their medication use through education, support, and by having compassion for their pain management and for their risk of overdose, as well as by working together to eliminate stigma regarding addiction and substance use disorders and by being the voice of those at risk and advocating with one another to prevent relapses/hospitalizations. When I witness patients having relapses that result in hospitalizations, I realize that we can do better in coordinating care and support with each other, but also with other health care professionals.

Populations that are impacted the most by opioid addiction include chronic pain patients who develop opiate addiction by being prescribed opiates for their pain management, and people who have co-existing mental health disorders/accompanies with their opiate addiction. Many rural and low-income urban areas also experience a large proportion of both populations of patients because these communities do not have adequate access to treatment and MAT services (McCray et al., 2022). Additionally, Black, Hispanic, and American Indiana/Alaska Native patients experience drug overdose at a higher rate and have limited access to evidence-based nursing care and support related to substance use disorder.

Areas of Uncertainty

 There are important questions that are still unanswered about what the best nurse-led practices are to reduce the chance of relapse and maintain recovery in a variety of settings. Further study of the best way to integrate MAT into nursing is required. Evidence of uncertainty still exists regarding the best way to tackle stigma through nursing education and practice (Dydyk et al., 2025). Also, long-term outcomes of the community-based nursing interventions on OUD need more rigorous study.

Evaluating Solution Success Factors

There are multiple evidence-based strategies to combat the opioid outbreak. This entails an increase in MAT delivery in primary care and specialty clinics. These also involve increasing harm reduction measures like take-home naloxone and syringe exchange programs, and the creation of safe injection facilities (Bremer et al., 2023; Lin, 2022). One of the ways is to improve the use of prescription drug monitoring programs (PDMPs) to prevent inappropriate opioid prescribing (Horn et al., 2025). Lastly, it is critical for people to learn how to get non-opioid alternatives to pain management, such as CBT and physical therapy.

Without burdensome regulations to access MAT, i.e., buprenorphine and methadone, I believe that it is critical. It reduces overdose deaths directly as well as aids with recovery (Bremer et al., 2023). Additionally, proponents of harm reduction argue that naloxone and safe consumption spaces have saved lives – and that they have been effective in reducing emergency department visits and infectious disease transmission (Bremer et al., 2023). While this has been touted as a downside to reduced doctor shopping, some opiate prescribers say it has led to administrative burden and an unintended shift to illicit opioids (Horn et al., 2025).     

MAT expansion benefits are a significant mortality drop (up to 50% less overdose risk), increased connection to health services, and cost savings from fewer hospitalizations and criminal justice interactions (Bremer et al., 2023). Some challenging barriers are stigma among providers and patients, regulatory issues and barriers to reimbursement that restrict patient access to providers, and the possibility of medication diversion due to a lack of monitoring. The policy changes to remove waivers, proper reimbursement of MAT services, and public education in combating stigma of OUD treatment are all important steps in addressing these obstacles.

Applying Ethical Care Principles

 Expanding MAT access would need a policy shift for the authorisation of nurses and physicians to prescribe buprenorphine and methadone, extensive training available for providers on health-related substance use disorder, and adequate payment schemes for MAT (Madras et al., 2020). It would also have to be well connected with mental health and social support services. Effective monitoring programs need to be in place to keep an eye on patient outcomes and diversion risks, with campaigns to escape stigma and educate the general public about treatment options. The overriding principle of beneficence for clinicians is to ensure the welfare of the patient, and the mortality benefits of MAT are well established as a nearly half reduction of deaths. Easy access to buprenorphine programs and methadone programs is another form of beneficence, actively promoting the prospect of recovery and a better quality of life (Horn et al., 2025). Nonmaleficence “is the obligation to do the least of all evil” (Olejarczyk & Young, 2024), and in the MAT context is the monitoring to prevent medication diversion and the management of negative consequences. Three simple steps to achieve this are regular follow-up visits, urine testing, and co-prescription of naloxone. 

Autonomy refers to the patient’s exercise of choices with regard to the care they receive. Nurses play a crucial role in educating individuals on the benefits and potential side effects of MAT, ensuring that patients are aware of their options and empowered to make informed decisions (Olejarczyk & Young, 2024). Use of shared decision-making can also help to enable patients to establish their own goals to assist them in their recovery. Finally, fair access to care includes MAT programs specifically targeting areas with providers in low numbers and underserved, such as rural areas and low-income urban neighborhoods, while also working to address issues with racial disparities that negatively impact American Indian/Alaska Native, Black, and Hispanic communities (Olejarczyk & Young, 2024). All should have equal access to the resources, and impediments to optimal treatment should be eliminated. But to reduce inaccuracies, healthcare providers must be educated on cultural competence and the reduction of implicit bias; stereotypes must not inhibit access to MAT (Humphreys et al., 2022). Regular reviews of who is referred to whom and what happens may identify inequities and redirect the efforts.

Improving Care Across Spheres

Increased access to MAT benefits directly benefits the wellness and disease prevention aspects by decreasing the risk of overdose death and preventing prescription opioid use from transitioning to illicit substance use. Providing buprenorphine or methadone in a primary care setting encourages patients to “show up sooner” by supporting (Jalali et al., 2020) education about overdose prevention and overdose reversal. This also provides the added benefit of lessening the chance of causing troublesome issues, for example infectious diseases and organ damage, linked to untreated OUD. Facilitated by community outreach and co-prescribing naloxone with community prescriptions, prevention strategies are integrated into everyday health care, helping to protect people and their families from crisis.

Opioid addiction in the context of chronic disease management is regarded as diabetes or hypertension and treated as a chronic condition that demands continual treatment. The use of MAT takes the edge off the roller coaster of withdrawal symptoms and drug craving, helping patients stay committed to other treatment recommendations, such as counseling, behavioral therapy, and plans to treat underlying conditions or disorders (Fenske et al., 2021). By monitoring regularly and collaborating with other professionals, clinicians can help tweak doses, take care of underlying mental health concerns, and pursue other options for pain management that can help keep a patient stable instead of episodic. When results are integrated at all of these levels, a healthcare system shifts from crisis management to a comprehensive system in which harm is prevented, a chronic, relapsing disease is managed, and patients are able to live full, happy lives.

Conclusion

Although MAT is an effective treatment, systemic, geographic, and social factors continue to limit access to it, and the opioid epidemic continues to affect individuals and communities throughout the U.S. in extreme ways. This issue needs to be addressed through a multi-dimensional, moral framework, with a key emphasis on increasing availability of MAT, decreasing stigma, better coordinating care, and equity among racial and socioeconomic groups.